Extended Data Fig. 6: ILC2 gating strategy and frequency in parabiotic PDAC mice.
From: IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
a, Frequency of KLRG1+ ILC2s in blood of rIL-33-treated PDAC mice. b-d, Experimental schema and gating strategy (b) of donor and recipient KLRG1+ ILC2s in recipient blood. Gating (c) and frequency of donor-derived non-ILCs (c bottom), KLRG1− ILC2s (d top) and CD45+ cells (d bottom) in recipient blood and tumours. e, Gating in sham and photoconverted KikGR PDAC mice as in Fig. 4b; gated on KLRG1+ ILC2s. Data collected 7 (a-d, blood) and 14 (c, d, tumour) days after tumour implantation, pooled from ≥2 independent experiments with n ≥ 3 mice per group with consistent results. n = individual tumours or organs from individual mice analysed separately. Horizontal bars = median. P values by two-tailed Mann-Whitney test (a, c, d).
